WHO greenlights Takeda's dengue vaccine as company plans to 're-engage' with FDA

15 May 2024
endpts.com
VaccineEmergency Use AuthorizationClinical StudyDrug Approval
The World Health Organization prequalified Takeda’s new dengue vaccine on Wednesday, a year after the company withdrew its FDA application for the candidate — though the company now says it will soon “re-engage” with the FDA.
The WHO wrote in a statement that the vaccine, known as TAK-003 or Qdenga, is recommended for children 6 to 16 years old in areas with a burden and transmission of dengue, adding that the vaccine should be administered in a two-dose schedule with a three-month interval between doses.
WHO greenlights Takeda's dengue vaccine as company plans to 're-engage' with FDA
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.